Development of 99m Tc-Labeled Complexes with a Niraparib HYNIC Derivative for PARP-Positive Tumor Imaging
Molecular Pharmaceutics · 03.02.2025 · 22 (2) · 1010-1019
DOI: 10.1021/acs.molpharmaceut.4c01237 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 08.01.2025. Verfasst von Qianna Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Radiopharmaceuticals of the Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (Nationa…. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Piperidines, Technetium, Indazoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China, Beijing Nova Program.
Abstract (Originalsprache)
As an enzyme that plays an important role in DNA repair, poly(ADP-ribose) polymerase-1 (PARP-1) has become a popular target for cancer therapy. Nuclear medicine molecular imaging technology, supplemented by radiolabeled PARP-1 inhibitors, can accurately determine the expression level of PARP-1 at lesion sites to help patients choose an appropriate treatment plan. In this work, niraparib was modified with a hydrazinonicotinamide (HYNIC) group to generate the ligand NPBHYNIC, which has an in vitro affinity (IC50) of 450.90 nM for PARP-1. The ligand NPBHYNIC was labeled with technetium-99m and six different coligands to yield [99mTc]Tc-(X/tricine)-NPBHYNIC (X = TPPTS, TPPMS, PSA, PDA, NIC and ISONIC). These complexes were hydrophilic and exhibited good stability in vitro, and low levels of these complexes were taken up by nontarget organs and tissues in Kunming mice. Among these complexes, [99mTc]Tc-(TPPTS/tricine)-NPBHYNIC and [99mTc]Tc-(NIC/tricine)-NPBHYNIC were selected for biodistribution in HeLa tumor-bearing BALB/c nude mice at 2 h post injection. The results revealed that the tumor uptake of [99mTc]Tc-(TPPTS/tricine)-NPBHYNIC (1.02 ± 0.07% ID/g) was greater than that of [99mTc]Tc-(NIC/tricine)-NPBHYNIC (0.36 ± 0.05% ID/g). Additionally, in biodistribution, single-photon emission computed tomography/computed tomography (SPECT/CT) and radioautography experiments, the tumor uptake of [99mTc]Tc-(TPPTS/tricine)-NPBHYNIC was significantly reduced in the blocked group, indicating PARP-1 specificity. Therefore, it has potential for use as a niraparib-based tumor imaging agent that targets PARP-1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Radiopharmaceuticals of the Ministry of Education, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), College of Chemistry, Beijing Norm…
- Department of Isotopes, China Institute of Atomic Energy, P.O. Box 2108, Beijing 102413, P. R. China.
- Key Laboratory of Beam Technology of the Ministry of Education, School of Physics and Astronomy, Beijing Normal University, Beijing 100875, P. R. China.
ORCID-Profile: Yuhao Jiang, Qing Ruan, Junbo Zhang
Förderung
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
- Beijing Nova Program
Zitieren
APA
Wang, Q., Feng, J., Jiang, Y., Ruan, Q., Yin, G., Han, P., & Zhang, J. (2025). Development of 99m Tc-Labeled Complexes with a Niraparib HYNIC Derivative for PARP-Positive Tumor Imaging. Molecular Pharmaceutics, 22(2), 1010-1019. https://doi.org/10.1021/acs.molpharmaceut.4c01237
Vancouver
Wang Q, Feng J, Jiang Y, Ruan Q, Yin G, Han P, et al. Development of 99m Tc-Labeled Complexes with a Niraparib HYNIC Derivative for PARP-Positive Tumor Imaging. Molecular Pharmaceutics. 2025;22(2):1010-1019. doi:10.1021/acs.molpharmaceut.4c01237
BibTeX
@article{Wang2025,
author = {Wang, Qianna and Feng, Junhong and Jiang, Yuhao and Ruan, Qing and Yin, Guangxing and Han, Peiwen and Zhang, Junbo},
title = {Development of 99m Tc-Labeled Complexes with a Niraparib HYNIC Derivative for PARP-Positive Tumor Imaging},
journal = {Molecular Pharmaceutics},
year = {2025},
volume = {22},
number = {2},
pages = {1010--1019},
doi = {10.1021/acs.molpharmaceut.4c01237}
}
EUVIMED